Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Fruquintinib × Tegafur × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 20 Colorectal Neoplasms 6 Carcinoma, Hepatocellular 6 Colonic Neoplasms 5 Rectal Neoplasms 4 Esophageal Squamous Cell Carcinoma 4 Unspecified Adult Solid Tumor, Protocol Specific 3 Pancreatic Neoplasms 3 Biliary Tract Neoplasms 3 HER2-positive Gastric Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Stage IA Pancreatic Adenocarcinoma 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Recurrence 1 Nasopharyngeal Carcinoma 1 Mouth Neoplasms 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Gallbladder Neoplasms 1 Fruquintinib 1 Epstein-Barr Virus Infections 1 Efficacy and Safety 1 Drug-Related Side Effects and Adverse Reactions 1 Cholangiocarcinoma 1 Advanced Biliary Tract Carcinoma 1

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 Irinotecan 1 HMPL-013 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡